📊 CDRE Key Takeaways
Is Cadre Holdings, Inc. (CDRE) a Good Investment?
Cadre Holdings demonstrates solid operational fundamentals with healthy revenue growth of 7.5% YoY and strong free cash flow generation of $56.8M (9.3% FCF margin). The company maintains excellent financial health with a 3.5x current ratio, robust interest coverage of 41.1x, and moderate leverage at 0.92x debt-to-equity, providing flexibility for strategic investments or debt reduction.
Cadre Holdings shows solid fundamental quality, with healthy revenue growth, strong gross margins, and disciplined cash conversion supported by low capital intensity. The balance sheet is liquid and debt appears manageable given very high interest coverage, though flat net income suggests margin expansion and earnings growth should be monitored more closely.
Why Buy Cadre Holdings, Inc. Stock? CDRE Key Strengths
- Strong liquidity position with $122.9M cash and 3.5x current ratio enabling operational flexibility
- Excellent interest coverage ratio of 41.1x indicating minimal financial distress risk
- Robust free cash flow generation of $56.8M with 9.3% FCF margin supporting shareholder returns or growth investments
- Healthy gross margin of 42.5% demonstrating pricing power and operational efficiency in surgical appliances sector
- Moderate leverage of 0.92x debt-to-equity providing balance sheet stability
- Strong liquidity profile with a 3.50x current ratio and 2.54x quick ratio
- Healthy profitability, including 42.5% gross margin and double-digit operating margin
- Consistent cash generation with $56.85M of free cash flow and a 9.3% FCF margin
CDRE Stock Risks: Cadre Holdings, Inc. Investment Risks
- Revenue growth of 7.5% is modest for a specialized medical devices company, suggesting market maturity or competitive pressures
- Net income flat YoY despite revenue growth indicates margin compression or increased operating expenses requiring investigation
- Long-term debt of $291M represents 37.8% of total assets, limiting financial flexibility despite manageable coverage ratios
- Operating margin of 11.0% is relatively thin for orthopedic/surgical appliances sector, leaving limited buffer for cost increases
- Net income was flat year over year despite 7.5% revenue growth, indicating limited operating leverage
- Debt remains meaningful at 0.92x debt-to-equity with $290.99M in long-term debt
- Moderate net margin of 7.2% leaves some sensitivity to cost inflation or mix shifts
Key Metrics to Watch
- Revenue growth rate trend and gross margin stability in coming quarters
- Operating cash flow sustainability and capital expenditure requirements for R&D
- Debt reduction progress and leverage trajectory relative to operating cash generation
- Operating margin expansion opportunities through operational leverage on revenue growth
- Net income and operating margin progression relative to revenue growth
- Free cash flow conversion and debt reduction trends
Cadre Holdings, Inc. (CDRE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.50x current ratio provides a solid financial cushion.
CDRE Profit Margin, ROE & Profitability Analysis
CDRE vs Healthcare Sector: How Cadre Holdings, Inc. Compares
How Cadre Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cadre Holdings, Inc. Stock Overvalued? CDRE Valuation Analysis 2026
Based on fundamental analysis, Cadre Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cadre Holdings, Inc. Balance Sheet: CDRE Debt, Cash & Liquidity
CDRE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cadre Holdings, Inc.'s revenue has grown significantly by 43% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.02 reflects profitable operations.
CDRE Revenue Growth, EPS Growth & YoY Performance
CDRE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $109.4M | $3.7M | $0.09 |
| Q2 2025 | $144.3M | $6.9M | $0.30 |
| Q1 2025 | $130.1M | $6.9M | $0.18 |
| Q3 2024 | $109.4M | $3.7M | $0.09 |
| Q2 2024 | $121.1M | $6.9M | $0.29 |
| Q1 2024 | $111.7M | $6.9M | $0.18 |
| Q3 2023 | $111.6M | -$779.0K | $-0.02 |
| Q2 2023 | $118.2M | $4.4M | $0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cadre Holdings, Inc. Dividends, Buybacks & Capital Allocation
CDRE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cadre Holdings, Inc. (CIK: 0001860543)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CDRE
What is the AI rating for CDRE?
Cadre Holdings, Inc. (CDRE) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CDRE's key strengths?
Claude: Strong liquidity position with $122.9M cash and 3.5x current ratio enabling operational flexibility. Excellent interest coverage ratio of 41.1x indicating minimal financial distress risk. ChatGPT: Strong liquidity profile with a 3.50x current ratio and 2.54x quick ratio. Healthy profitability, including 42.5% gross margin and double-digit operating margin.
What are the risks of investing in CDRE?
Claude: Revenue growth of 7.5% is modest for a specialized medical devices company, suggesting market maturity or competitive pressures. Net income flat YoY despite revenue growth indicates margin compression or increased operating expenses requiring investigation. ChatGPT: Net income was flat year over year despite 7.5% revenue growth, indicating limited operating leverage. Debt remains meaningful at 0.92x debt-to-equity with $290.99M in long-term debt.
What is CDRE's revenue and growth?
Cadre Holdings, Inc. reported revenue of $610.3M.
Does CDRE pay dividends?
Cadre Holdings, Inc. pays dividends, with $15.4M distributed to shareholders in the trailing twelve months.
Where can I find CDRE SEC filings?
Official SEC filings for Cadre Holdings, Inc. (CIK: 0001860543) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CDRE's EPS?
Cadre Holdings, Inc. has a diluted EPS of $1.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CDRE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cadre Holdings, Inc. has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is CDRE stock overvalued or undervalued?
Valuation metrics for CDRE: ROE of 13.9% (sector avg: 15%), net margin of 7.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CDRE stock in 2026?
Our dual AI analysis gives Cadre Holdings, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CDRE's free cash flow?
Cadre Holdings, Inc.'s operating cash flow is $63.7M, with capital expenditures of $6.9M. FCF margin is 9.3%.
How does CDRE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 7.2% (avg: 12%), ROE 13.9% (avg: 15%), current ratio 3.50 (avg: 2).